NAMs Atlas
The technologies, companies, deals, regulation and research replacing animal testing in drug development and chemical safety.
Updated weekly. Last update: Oct 23, 2026
Coverage: v1 tracks deals and companies with a public source. It is not a census. Figures are lower bounds.
Latest updates
All updates- Oct 22, 2026News
NIH ORIVA holds workshop on human-based models
ORIVA's innovation division convened a one-day workshop on current human-based models and their use in disease research.
ntp.niehs.nih.gov(opens in new tab)confirmed - Oct 21, 2026News
EFSA workshop on applying the EU roadmap to pesticides and biocides
Two-day workshop in Parma on implementing the Commission roadmap in pesticide and biocide assessments.
efsa.europa.eu(opens in new tab)confirmed - Oct 8, 2026RegulatoryAustralia
TGA publishes its position on NAMs
Weight-of-evidence approach. NAMs may need to run alongside animal studies where uncertainty remains.
tga.gov.au(opens in new tab)confirmed - Oct 6, 2026NewsPBPK, QSP & biosimulation
EFSA publishes scoping review of in silico and PBK models
External scientific report reviewing existing in silico and physiologically based kinetic models for humans and rats.
efsa.europa.eu(opens in new tab)confirmed - Sep 22, 2026RegulatoryUS
SystImmune reports IND clearance with a NAM-based safety package
Company says organ-on-chip and primary human tissue models replaced conventional animal toxicology for bispecific SI-B037. FDA has not commented publicly.
- Sep 17, 2026DealEngineered & bioprinted tissue
Polyphron: Venture financing, Seed
Seed to build an automated human tissue foundry and AI tissue models.
hlth.com(opens in new tab)confirmed - Sep 17, 2026Publication
New approach methodologies in neurotherapeutics development
Government, academic and industry view of NAMs for CNS drugs, including blood-brain barrier and neurotoxicity models.
- Sep 9, 2026RegulatoryUS
Emulate files full qualification package for Liver-Chip
Final step of three in ISTAND. If FDA qualifies it, it would be the first organ-chip drug development tool, for DILI assessment.
emulatebio.com(opens in new tab)confirmed
Deals by year
Disclosed venture capital by year
Companies by segment
Key numbers
Organ-on-chip companies (Tracxn census)
Across 16 countries.
Equity raised by organ-on-chip companies, cumulative
67 equity rounds.
Organoid research model startups
79 funded; 19 at Series A or later.
NAM submissions to FDA CDER that are in silico or in vitro
15-year analysis of submissions. 3D and organ-chip models were less common than conventional in vitro models.
Animals used for EU regulatory testing, 2015 to 2023
Nearly 40% in chemical safety assessments.
Tools fully qualified through FDA ISTAND
Per FDA metrics dated Jan 1, 2026. Eight submissions were accepted during the pilot. Emulate filed a full package in Sep 2026.
NIH Complement-ARIE first awards
Plus about $20M for the validation network and a $7M challenge.
ARPA-H CATALYST budget for computational drug safety models
Over 4.5 years. Eight performer teams named Dec 2025.
Certara revenue, FY2024
Largest public pure play in biosimulation.
Simulations Plus revenue, FY2025
FY2026 guidance $79M to $82M.
Charles River revenue it called at risk from FDA's NAM push
Longer chronic NHP antibody studies. Management expected no immediate impact.
Price Sartorius paid for MatTek
MatTek had more than $20M of 2024 sales, so under 4x sales.
Emulate cumulative private funding
Last priced round an $82M Series E in 2021.
Regulatory timeline, 2025 to today
Full timeline- Apr 10, 2025 · US
FDA roadmap to reduce animal testing in preclinical safety studies
Published - Apr 29, 2025 · US
NIH initiative to prioritize human-based research
Announced - Jul 2025 · US
NIH stops issuing animal-only funding opportunities
In effect - Aug 2025 · US
NIH unified strategy on human-based NAMs
Published - Aug 4, 2025 · EU
EMA qualification opinion for the Simcyp PBPK platform
Final - Sep 30, 2025 · US
Complement-ARIE Reduction to Practice Prize launched
Open - Nov 11, 2025 · UK
UK strategy: Replacing animals in science
Published - Dec 2, 2025 · US
Draft guidance: monoclonal antibodies, streamlined nonclinical safety studies
Draft - Dec 4, 2025 · US
ARPA-H names CATALYST performer teams
Awarded - Dec 16, 2025 · US
Senate passes FDA Modernization Act 3.0 (S.355)
Passed one chamber - Jan 22, 2026 · US
EPA recommits to ending mammalian testing by 2035
In effect - Mar 2026 · US
Endotoxin testing Q&A update backs non-animal reagents
Final - Mar 18, 2026 · US
Complement-ARIE first awards ($150M+)
Awarded - Mar 18, 2026 · US
Draft guidance: General Considerations for the Use of NAMs in Drug Development
Draft - Apr 20, 2026 · US
FDA Year One progress report on reducing animal testing
Published - May 19, 2026 · International
C-Path launches NAMs Developer Coalition
Launched - May 29, 2026 · US
Draft guidance: oncology biologics and conjugates, streamlined nonclinical safety
Draft - Jun 1, 2026 · EU
EU roadmap to phase out animal testing in chemical safety assessments
Adopted - Jun 2, 2026 · US
EPA updates its accepted NAMs list for TSCA and FIFRA
In effect - Jun 15, 2026 · US
NIH formally launches ORIVA
Launched - Jul 20, 2026 · US
House passes FDA Modernization Act 3.0 (H.R. 2821)
Pending - Aug 27, 2026 · US
EPA announces changes to new chemical and pesticide reviews
Announced - Sep 9, 2026 · US
Emulate files full qualification package for Liver-Chip
Under review - Sep 22, 2026 · US
SystImmune reports IND clearance with a NAM-based safety package
Completed - Oct 8, 2026 · Australia
TGA publishes its position on NAMs
Published